CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV) today announced that the company will be holding its first-ever symposium at the 2016 Spine Summit meeting on Thursday, March 17, 2016 in Orlando, FL. The meeting is the 32nd Annual Meeting of the AANS/CNS (American Associations of Neurological Surgeons / Congress of Neurological Surgeons) Joint Section on Disorders of the Spine and Peripheral Nerves and is being held in collaboration with 11 other spine societies.
The symposium presentation is titled “Innovation in Spinal Cord Injury Treatment: The Investigational Neuro-Spinal Scaffold™ and Bioengineered Neural Trails™” and will feature presentations by three renowned key opinion leaders: Robert Langer, Sc.D., the David H. Koch Institute Professor at Massachusetts Institute of Technology and co-founder of InVivo; Nicholas Theodore, M.D., Chief of Spinal Surgery at the Barrow Neurosurgical Institute and the neurosurgeon who performed the first Neuro-Spinal Scaffold™ implantation; and James Guest, M.D., Ph.D., Professor of Clinical Neurosurgery at the University of Miami’s Miller School of Medicine and inventor on the novel cell delivery patent InVivo recently acquired.
In addition to the symposium, Dr. Theodore will be giving an oral platform presentation titled “Neurologic Outcome Following Implantation of a Neuro-Spinal Scaffold™ into the Lesion Cavity in Acute Thoracic Complete Spinal Cord Injury: Results of a Pilot Study” during the Trauma and Spinal Cord Injury session on Friday, March 18, 2016. The presentation will highlight his firsthand experience with the investigational Neuro-Spinal Scaffold and the results of The INSPIRE Study to date.
InVivo will have several other engagement opportunities, including a What’s New session and an exhibitor booth.
“Cultivating mindshare in the neurosurgical community has been a significant initiative at InVivo as we progress through The INSPIRE Study. Hosting a symposium at a meeting that involves AANS and CNS, the two largest American neurosurgical societies, provides us a fantastic opportunity to provide updates to the neurosurgeons who have been following our progress and to introduce new neurosurgeons to our innovative approaches to treating acute and chronic spinal cord injury,” Mark Perrin, InVivo’s CEO and Chairman, said.
About the Neuro-Spinal Scaffold™ Implant
Following an acute spinal cord injury, the biodegradable Neuro-Spinal Scaffold is surgically implanted at the epicenter of the wound and is designed to act as a physical substrate for nerve sprouting. Appositional healing to spare spinal cord tissue, decreased post-traumatic cyst formation, and decreased spinal cord tissue pressure have been demonstrated in preclinical models of spinal cord contusion injury. The Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and currently is being evaluated in the INSPIRE pivotal probable benefit study for the treatment of patients with complete (AIS A) traumatic acute spinal cord injury.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company’s investigational Neuro-Spinal Scaffold received the 2015 Becker’s Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.